No abstract available
Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study / Kastritis E.; Terpos E.; Symeonidis A.; Labropoulou V.; Delimpasi S.; Mancuso K.; Zamagni E.; Katodritou E.; Rivolti E.; Kyrtsonis M.-C.; Roussou M.; Fotiou D.; Theodorakakou F.; Ntanasis-Stathopoulos I.; Hatjiharissi E.; Kanellias N.; Migkou M.; Cheliotis G.; Manousou K.; Gavriatopoulou M.; Dimopoulos M.A.. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 0361-8609. - ELETTRONICO. - 98:9(2023), pp. E226-E229. [10.1002/ajh.27001]
Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study
Mancuso K.;Zamagni E.;
2023
Abstract
No abstract availableFile in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
